The Administration Core will provide executive oversight and administrative support for all of the projects and cores that comprise the Leukemia SPORE. The goal of the Administration Core is to monitor the activities of all of the program components, to comply with all local and federal guideline for grant administration, and to facilitate communication and collaboration among the program members. Accordingly, the specific aims of the Administration Core are as follows:
Aim 1. To facilitate intra- and inter-SPORE communication and collaboration. We will organize monthly SPORE meetings and the development and maintenance of a Leukemia SPORE web site.
Aim 2. To provide administrative and fiscal oversight and support for all SPORE components. This core will be responsible for interacting with the Grants and Contracts Office at Washington University and with staff at the NCI, including preparation and submission of annual progress reports.
Aim 3. To coordinate all SPORE-related meetings. This core will coordinate the meetings of the External Advisory Board, attendance at the annual SPORE workshop, and monthly meetings of the Leukemia SPORE Steering Committee.
Aim 4. To coordinate administrative activities of the SPORE Developmental Research Program. This core will solicit applications for pilot projects and coordinate the review of these applications.
Aim 5. To coordinate the SPORE Career Development Program. This core will assist in the recruitment and monitoring of candidates in this program.
Aim 6. To assist investigators with the preparation of scholarly presentations, publications, regulatory documents, and all other SPORE-related paperwork.
Aim 7. To enhance participation of minorities in SPORE activities.
Aim 8. To ensure advocacy issues are addressed and included in all aspects fo research with patient participants.
|Ghobadi, Armin; Choi, Jaebok; Fiala, Mark A et al. (2016) Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation. Leuk Res 49:1-6|
|Al-Hussaini, Muneera; Rettig, Michael P; Ritchey, Julie K et al. (2016) Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform. Blood 127:122-31|
|Welch, John S; Petti, Allegra A; Miller, Christopher A et al. (2016) TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. N Engl J Med 375:2023-2036|
|Rashidi, Armin; Ebadi, Maryam; Colditz, Graham A et al. (2016) Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. Biol Blood Marrow Transplant 22:651-7|
|Fehniger, Todd A; Cooper, Megan A (2016) Harnessing NK Cell Memory for Cancer Immunotherapy. Trends Immunol 37:877-888|
|Wong, Terrence N; Miller, Christopher A; Klco, Jeffery M et al. (2016) Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML. Blood 127:893-7|
|Rashidi, Armin; Walter, Roland B; Tallman, Martin S et al. (2016) Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials. Blood 128:763-73|
|Shirai, Cara Lunn; Ley, James N; White, Brian S et al. (2015) Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo. Cancer Cell 27:631-43|
|Wong, Terrence N; Ramsingh, Giridharan; Young, Andrew L et al. (2015) Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 518:552-5|
|Uy, Geoffrey L; Hsu, Yen-Michael S; Schmidt, Amy P et al. (2015) Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia. Leuk Res 39:1437-42|
Showing the most recent 10 out of 32 publications